Search

Your search keyword '"Shah, Mithun Vinod"' showing total 127 results
Start Over Author "Shah, Mithun Vinod" Publication Year Range Last 3 years
127 results on '"Shah, Mithun Vinod"'

1. Clonal heterogeneity in STAG2m myeloid neoplasms: the Mayo Clinic experience

Author

Katamesh, Bahga, Nanaa, Ahmad, He, Rong, Viswanatha, David, Greipp, Patricia T., Bessonen, Kurt, Nguyen, Phuong, Jevremovic, Dragan, Yi, Cecilia Arana, Foran, James, Begna, Kebede, Gangat, Naseema, Mangaonkar, Abhishek, Saliba, Antoine N., Patnaik, Mrinal M., Hogan, William J, Litzow, Mark, Tefferi, Ayalew, Shah, Mithun Vinod, Alkhateeb, Hassan B, and Al-Kali, Aref

Published
2024
Full Text
View/download PDF

2. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

Author

Wang, Eunice S, Issa, Ghayas C, Erba, Harry P, Altman, Jessica K, Montesinos, Pau, DeBotton, Stephane, Walter, Roland B, Pettit, Kristen, Savona, Michael R, Shah, Mithun Vinod, Kremyanskaya, Marina, Baer, Maria R, Foran, James M, Schiller, Gary, Adès, Lionel, Heiblig, Mael, Berthon, Celine, Peterlin, Pierre, Rodríguez-Arbolí, Eduardo, Salamero, Olga, Patnaik, Mrinal M, Papayannidis, Cristina, Grembecka, Jolanta, Cierpicki, Tomasz, Clegg, Bradley, Ray, Joshua, Linhares, Brian M, Nie, Kun, Mitra, Amitava, Ahsan, Julie Mackey, Tabachri, Marilyn, Soifer, Harris S, Corum, Daniel, Leoni, Mollie, Dale, Stephen, and Fathi, Amir T

Published
2024
Full Text
View/download PDF

6. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms

Author

Shah, Mithun Vinod, Tran, Elizabeth Ngoc Hoa, Shah, Syed, Chhetri, Rakchha, Baranwal, Anmol, Ladon, Dariusz, Shultz, Carl, Al-Kali, Aref, Brown, Anna L., Chen, Dong, Scott, Hamish S., Greipp, Patricia, Thomas, Daniel, Alkhateeb, Hassan B., Singhal, Deepak, Gangat, Naseema, Kumar, Sharad, Patnaik, Mrinal M., Hahn, Christopher N., Kok, Chung Hoow, Tefferi, Ayalew, and Hiwase, Devendra K.

Published
2023
Full Text
View/download PDF

9. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis

Author

Murthy, Hemant S., Zhang, Mei-Jie, Chen, Karen, Ahmed, Sairah, Deotare, Uday, Ganguly, Siddhartha, Kansagra, Ankit, Michelis, Fotios V., Nishihori, Taiga, Patnaik, Mrinal, Abid, Muhammad Bilal, Aljurf, Mahmoud, Arai, Yasuyuki, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Ballen, Karen, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Martino, Rodrigo, Cahn, Jean-Yves, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Copelan, Edward, Daly, Andrew, Dholaria, Bhagirathbhai, Diaz Perez, Miguel Angel, Freytes, César O., Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Jamy, Omer, Joseph, Jacinth, Kanakry, Christopher G., Khera, Nandita, Krem, Maxwell M., Kuwatsuka, Yachiyo, Lazarus, Hillard M., Lekakis, Lazaros J., Liu, Hongtao, Modi, Dipenkumar, Munshi, Pashna N., Mussetti, Alberto, Palmisiano, Neil, Patel, Sagar S., Rizzieri, David A., Seo, Sachiko, Shah, Mithun Vinod, Sharma, Akshay, Sohl, Melhm, Solomon, Scott R., Ulrickson, Matthew, Ustun, Celalettin, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Wang, Trent, Wirk, Baldeep, Zeidan, Amer, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Weisdorf, Daniel J., Saber, Wael, and Kharfan-Dabaja, Mohamed A.

Published
2023
Full Text
View/download PDF

11. Impact of second primary malignancy postautologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Author

Ragon, Brittany Knick, Shah, Mithun Vinod, D’Souza, Anita, Estrada-Merly, Noel, Gowda, Lohith, George, Gemlyn, de Lima, Marcos, Hashmi, Shahrukh, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Banerjee, Rahul, Saad, Ayman, Hildebrandt, Gerhard C., Mian, Hira, Abid, Muhammad Bilal, Battiwalla, Minoo, Lekakis, Lazaros J., Patel, Sagar S., Murthy, Hemant S., Nieto, Yago, Strouse, Christopher, Badawy, Sherif M., Al Hadidi, Samer, Dholaria, Bhagirathbhai, Aljurf, Mahmoud, Vesole, David H., Lee, Cindy H., Pawarode, Attaphol, Gergis, Usama, Miller, Kevin C., Holmberg, Leona A., Afrough, Aimaz, Solh, Melhem, Munshi, Pashna N., Nishihori, Taiga, Anderson, Larry D., Jr., Wirk, Baldeep, Kaur, Gurbakhash, Qazilbash, Muzaffar H., Shah, Nina, Kumar, Shaji K., and Usmani, Saad Z.

Published
2023
Full Text
View/download PDF

12. Autoimmune manifestations in STAG2-mutated myeloid neoplasms

Author

Katamesh, Bahga, Nanaa, Ahmad, He, Rong, Viswanatha, David, Nguyen, Phuong, Greipp, Patricia, Foran, James, Begna, Kebede, Gangat, Naseema, Patnaik, Mrinal, Tefferi, Ayalew, Litzow, Mark, Mangaonkar, Abhishek, Shah, Mithun Vinod, Badar, Talha, Alkhateeb, Hassan B., and Al-Kali, Aref

Published
2022
Full Text
View/download PDF

13. Factors before leukapheresis that correlate with severe cytopenia and therapy related myeloid neoplasm post CAR-T.

Author

De Menezes Silva Corraes, Andre, primary, Baranwal, Anmol, additional, Bansal, Radhika, additional, Gurney, Mark, additional, Rosenthal, Allison Claire, additional, Kharfan-Dabaja, Mohamed, additional, Khurana, Arushi, additional, Johnston, Patrick B., additional, Ansell, Stephen M., additional, Kapoor, Prashant, additional, Gertz, Morie A., additional, Kumar, Shaji, additional, Dingli, David, additional, Durani, Urshila, additional, Villasboas Bisneto, Jose, additional, Kenderian, Saad, additional, Alkhateeb, Hassan B., additional, Wang, Yucai, additional, Shah, Mithun Vinod, additional, and Lin, Yi, additional

Published
2024
Full Text
View/download PDF

19. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma

Author

Alkhateeb, Hassan B., Mohty, Razan, Greipp, Patricia, Bansal, Radhika, Hathcock, Matthew, Rosenthal, Allison, Murthy, Hemant, Kharfan-Dabaja, Mohamed, Bisneto Villasboas, Jose C., Bennani, Nora, Ansell, Stephen M., Patnaik, Mrinal M., Litzow, Mark R., He, Rong, Chen, Dong, Al-Kali, Aref, Kenderian, Saad S., Lin, Yi, and Shah, Mithun Vinod

Published
2022
Full Text
View/download PDF

20. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms

Author

Baranwal, Anmol, primary, Basmaci, Rami, additional, He, Rong, additional, Viswanatha, David, additional, Greipp, Patricia, additional, Murthy, Hemant S., additional, Foran, James, additional, Palmer, Jeanne, additional, Hogan, William J., additional, Litzow, Mark R., additional, Hefazi, Mehrdad, additional, Mangaonkar, Abhishek, additional, Shah, Mithun Vinod, additional, Al-Kali, Aref, additional, and Alkhateeb, Hassan B., additional

Published
2024
Full Text
View/download PDF

22. Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy

Author

Xie, Zhuoer, primary, Lasho, Terra, additional, Khurana, Arushi, additional, Ferrer, Alejandro, additional, Finke, Christy, additional, Mangaonkar, Abhishek A., additional, Ansell, Stephen, additional, Fernandez, Jenna, additional, Shah, Mithun Vinod, additional, Al-Kali, Aref, additional, Gangat, Naseema, additional, Abeykoon, Jithma, additional, Witzig, Thomas E., additional, and Patnaik, Mrinal M., additional

Published
2023
Full Text
View/download PDF

23. Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience

Author

Katamesh, Bahga, primary, Nanaa, Ahmad, additional, He, Rong, additional, Viswanatha, David, additional, Nguyen, Phuong, additional, Greipp, Patricia, additional, Bessonen, Kurt, additional, Gangat, Naseema, additional, Begna, Kebede, additional, Mangaonkar, Abhishek, additional, Patnaik, Mrinal, additional, Hogan, William J., additional, Tefferi, Ayalew, additional, Litzow, Mark, additional, Shah, Mithun Vinod, additional, Yi, Cecilia Arana, additional, Foran, James, additional, Badar, Talha, additional, Alkhateeb, Hassan B., additional, and Al-Kali, Aref, additional

Published
2023
Full Text
View/download PDF

24. Impact of Second Primary Malignancy Post–Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis

Author

Ragon, Brittany Knick, Shah, Mithun Vinod, D'Souza, Anita, Estrada-Merly, Noel, Gowda, Lohith, George, Gemlyn, de Lima, Marcos, Hashmi, Shahrukh, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Banerjee, Rahul, Saad, Ayman, Hildebrandt, Gerhard C., Mian, Hira, Abid, Muhammad Bilal, Battiwalla, Minoo, Lekakis, Lazaros J., Patel, Sagar S., Murthy, Hemant S., Nieto, Yago, Strouse, Christopher, Badawy, Sherif M., Al Hadidi, Samer, Dholaria, Bhagirathbhai, Aljurf, Mahmoud, Vesole, David H., Lee, Cindy H., Pawarode, Attaphol, Gergis, Usama, Miller, Kevin C., Holmberg, Leona A., Afrough, Aimaz, Solh, Melhem, Munshi, Pashna N., Nishihori, Taiga, Anderson, Larry D., Wirk, Baldeep, Kaur, Gurbakhash, Qazilbash, Muzaffar H., Shah, Nina, Kumar, Shaji K., Usmani, Saad Z., Ragon, Brittany Knick, Shah, Mithun Vinod, D'Souza, Anita, Estrada-Merly, Noel, Gowda, Lohith, George, Gemlyn, de Lima, Marcos, Hashmi, Shahrukh, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Banerjee, Rahul, Saad, Ayman, Hildebrandt, Gerhard C., Mian, Hira, Abid, Muhammad Bilal, Battiwalla, Minoo, Lekakis, Lazaros J., Patel, Sagar S., Murthy, Hemant S., Nieto, Yago, Strouse, Christopher, Badawy, Sherif M., Al Hadidi, Samer, Dholaria, Bhagirathbhai, Aljurf, Mahmoud, Vesole, David H., Lee, Cindy H., Pawarode, Attaphol, Gergis, Usama, Miller, Kevin C., Holmberg, Leona A., Afrough, Aimaz, Solh, Melhem, Munshi, Pashna N., Nishihori, Taiga, Anderson, Larry D., Wirk, Baldeep, Kaur, Gurbakhash, Qazilbash, Muzaffar H., Shah, Nina, Kumar, Shaji K., and Usmani, Saad Z.

Abstract

The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with the use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) and subsequent maintenance therapies in eligible newly diagnosed patients. However, clinical trials using auto-HSCT followed by lenalidomide maintenance have shown an increased risk of second primary malignancies (SPM), including second hematological malignancies (SHM). We evaluated the impact of SPM and SHM on progression-free survival (PFS) and OS in patients with MM after auto-HSCT using CIBMTR registry data. Adult patients with MM who underwent first auto-HSCT in the United States with melphalan conditioning regimen from 2011 to 2018 and received maintenance therapy were included (n = 3948). At a median follow-up of 37 months, 175 (4%) patients developed SPM, including 112 (64%) solid, 36 (20%) myeloid, 24 (14%) SHM, not otherwise specified, and 3 (2%) lymphoid malignancies. Multivariate analysis demonstrated that SPM and SHM were associated with an inferior PFS (hazard ratio [HR] 2.62, P < .001 and HR 5.01, P < .001, respectively) and OS (HR 3.85, P < .001 and HR 8.13, P < .001, respectively). In patients who developed SPM and SHM, MM remained the most frequent primary cause of death (42% vs 30% and 53% vs 18%, respectively). We conclude the development of SPM and SHM leads to a poor survival in patients with MM and is an important survivorship challenge. Given the median survival for MM continues to improve, continued vigilance is needed to assess the risks of SPM and SHM with maintenance therapy post-auto-HSCT.

Published
2023

25. The Mutational Landscape in Chronic Myelomonocytic Leukemia and Its Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for Blood and Marrow Transplantation Research (CIBMTR) Analysis

Author

Mei, Matthew, Pillai, Raju, Kim, Soyoung, Estrada-Merly, Noel, Afkhami, Michelle, Yang, Lixin, Meng, Zhuo, Abid, Muhammad Bilal, Aljurf, Mahmoud, Bacher, Ulrike, Beitinjaneh, Amer, Bredeson, Christopher, Cahn, Jean-Yves, Cerny, Jan, Copelan, Edward, Cutler, Corey, DeFilipp, Zachariah, Diaz Perez, Miguel Angel, Farhadfar, Nosha, Freytes, César O, Gadalla, Shahinaz M, Ganguly, Siddhartha, Gale, Robert Peter, Gergis, Usama, Grunwald, Michael R, Hamilton, Betty K, Hashmi, Shahrukh, Hildebrandt, Gerhard C, Lazarus, Hillard M, Litzow, Mark, Munker, Reinhold, Murthy, Hemant S, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar S, Rizzieri, David, Seo, Sachiko, Shah, Mithun Vinod, Solh, Melhem, Verdonck, Leo F, Vij, Ravi, Sobecks, Ronald M, Oran, Betul, Scott, Bart L, Saber, Wael, Nakamura, Ryotaro, Mei, Matthew, Pillai, Raju, Kim, Soyoung, Estrada-Merly, Noel, Afkhami, Michelle, Yang, Lixin, Meng, Zhuo, Abid, Muhammad Bilal, Aljurf, Mahmoud, Bacher, Ulrike, Beitinjaneh, Amer, Bredeson, Christopher, Cahn, Jean-Yves, Cerny, Jan, Copelan, Edward, Cutler, Corey, DeFilipp, Zachariah, Diaz Perez, Miguel Angel, Farhadfar, Nosha, Freytes, César O, Gadalla, Shahinaz M, Ganguly, Siddhartha, Gale, Robert Peter, Gergis, Usama, Grunwald, Michael R, Hamilton, Betty K, Hashmi, Shahrukh, Hildebrandt, Gerhard C, Lazarus, Hillard M, Litzow, Mark, Munker, Reinhold, Murthy, Hemant S, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar S, Rizzieri, David, Seo, Sachiko, Shah, Mithun Vinod, Solh, Melhem, Verdonck, Leo F, Vij, Ravi, Sobecks, Ronald M, Oran, Betul, Scott, Bart L, Saber, Wael, and Nakamura, Ryotaro

Abstract

Somatic mutations are recognized as an important prognostic factor in chronic myelomonocytic leukemia (CMML). However, limited data are available regarding their impact on outcomes after allogeneic hematopoietic cell transplantation (HCT). In this registry analysis conducted in collaboration with the Center for International Blood and Marrow Transplantation Registry database/sample repository, we identified 313 adult patients with CMML (median age: 64 years, range, 28- 77) who underwent allogeneic HCT during 2001-2017 and had an available biospecimen in the form of a peripheral blood sample obtained prior to the start of conditioning. In multivariate analysis, a CMML-specific prognostic scoring system (CPSS) score of intermediate-2 (HR=1.46, P=0.049) or high (HR=3.22, P=0.0004) correlated significantly with overall survival. When the molecularly informed CPSS-Mol prognostic model was applied, a high CPSS-Mol score (HR=2 P=0.0079) correlated significantly with overall survival. The most common somatic mutations were in ASXL1 (62%), TET2 (35%), KRAS/NRAS (33% combined), and SRSF2 (31%). DNMT3A and TP53 mutations were associated with decreased overall survival (HR=1.70 [95% CI: 1.11-2.60], P=0.0147 and HR=2.72 [95% CI: 1.37-5.39], P=0.0042, respectively) while DNMT3A, JAK2, and TP53 mutations were associated with decreased disease-free survival (HR=1.66 [95% CI: 1.11-2.49], P=0.0138, HR=1.79 [95% CI: 1.06-3.03], P=0.0293, and HR=2.94 [95% CI: 1.50-5.79], P=0.0018, respectively). The only mutation associated with increased relapse was TP53 (HR=2.94, P=0.0201). Nonetheless, the impact of TP53 mutations specifically should be interpreted cautiously given their rarity in CMML. We calculated the goodness of fit measured by Harrell's C-index for both the CPSS and CPSS-Mol, which were very similar. In summary, via registry data we have determined the mutational landscape in patients with CMML who underwent allogeneic HCT, and demonstrated an association between CPSS-Mol and t

Published
2023

26. Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis

Author

Ragon, Brittany Knick, primary, Shah, Mithun Vinod, additional, D'Souza, Anita, additional, Estrada-Merly, Noel, additional, Gowda, Lohith, additional, George, Gemlyn, additional, DeLima, marcos, additional, Hashmi, Shahrukh, additional, Kharfan-Dabaja, Mohamed A, additional, Majhail, Navneet S, additional, Banerjee, Rahul, additional, Saad, Ayman, additional, Hildebrandt, Gerhard C., additional, Mian, Hira, additional, Abid, Muhammad Bilal, additional, Battiwalla, Minoo, additional, Lekakis, Lazaros J., additional, Patel, Sagar S., additional, Murthy, Hemant S., additional, Nieto, Yago, additional, Strouse, Christopher S, additional, Badawy, Sherif M., additional, Al Hadidi, Samer AI, additional, Dholaria, Bhagirathbhai, additional, Aljurf, Mahmoud, additional, Vesole, David H, additional, Lee, Cindy H, additional, Pawarode, Attaphol, additional, Gergis, Usama, additional, Miller, Kevin Charles, additional, Holmberg, Leona A, additional, Afrough, Aimaz, additional, Solh, Melhem M, additional, Munshi, Pashna, additional, Nishihori, Taiga, additional, Anderson, Larry D., additional, Wirk, Baldeep, additional, Kaur, Gurbakhash, additional, Qazilbash, Muzaffar H, additional, Shah, Nina, additional, Kumar, Shaji K, additional, and Usmani, Saad Z., additional

Published
2023
Full Text
View/download PDF

27. Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival

Author

Gangat, Naseema, primary, Kuykendall, Andrew T, additional, Al Ali, Najla H, additional, Goel, Swati, additional, Abdelmagid, Maymona, additional, Al-Kali, Aref, additional, Alkhateeb, Hassan B, additional, Begna, Kebede, additional, Mangaonkar, Abhishek A., additional, Litzow, Mark R, additional, Hogan, William J, additional, Shah, Mithun Vinod, additional, Patnaik, Mrinal M., additional, Pardanani, Animesh D, additional, Komrokji, Rami S., additional, and Tefferi, Ayalew, additional

Published
2023
Full Text
View/download PDF

28. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Author

Hiwase, Devendra K., primary, Hahn, Christopher N, additional, Tran, Elizabeth Ngoc Hoa, additional, Chhetri, Rakchha, additional, Baranwal, Anmol, additional, Al-Kali, Aref, additional, Sharplin, Kirsty M, additional, Ladon, Dariusz, additional, Hollins, Rachel, additional, Greipp, Patricia T., additional, Kutyna, Monika M., additional, Alkhateeb, Hassan B, additional, Badar, Talha, additional, Wang, Paul Po-Shen, additional, Ross, David M, additional, Singhal, Deepak, additional, Shanmuganathan, Naranie, additional, Bardy, Peter G, additional, Beligaswatte, Ashanka, additional, Yeung, David T, additional, Litzow, Mark R, additional, Mangaonkar, Abhishek A., additional, Giri, Pratyush, additional, Lee, Cindy H, additional, Yong, Angelina, additional, Horvath, Noemi, additional, Singhal, Nimit, additional, Gowda, Raghu, additional, Hogan, William J, additional, Gangat, Naseema, additional, Patnaik, Mrinal M., additional, Begna, Kebede, additional, Tiong, Ing Soo, additional, Wei, Andrew H, additional, Kumar, Sharad, additional, Brown, Anna L, additional, Scott, Hamish S, additional, Thomas, Daniel, additional, Kok, Chung Hoow, additional, Tefferi, Ayalew, additional, and Shah, Mithun Vinod, additional

Published
2022
Full Text
View/download PDF

29. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Author

Hiwase, Devendra, Hahn, Christopher, Tran, Elizabeth Ngoc Hoa, Chhetri, Rakchha, Baranwal, Anmol, Al-Kali, Aref, Sharplin, Kirsty, Ladon, Dariusz, Hollins, Rachel, Greipp, Patricia, Kutyna, Monika, Alkhateeb, Hassan, Badar, Talha, Wang, Paul, Ross, David M., Singhal, Deepak, Shanmuganathan, Naranie, Bardy, Peter, Beligaswatte, Ashanka, Yeung, David, Litzow, Mark R., Mangaonkar, Abhishek, Giri, Pratyush, Lee, Cindy, Yong, Angie, Horvath, Noemi, Singhal, Nimit, Gowda, Raghu, Hogan, William, Gangat, Naseema, Patnaik, Mrinal, Begna, Kebede, Tiong, Ing S., Wei, Andrew, Kumar, Sharad, Brown, Anna, Scott, Hamish, Thomas, Daniel, Kok, Chung H., Tefferi, Ayalew, and Shah, Mithun Vinod

Published
2023
Full Text
View/download PDF

30. Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms

Author

Katamesh, Bahga, primary, Nanaa, Ahmad, additional, He, Rong, additional, Viswanatha, David, additional, Nguyen, Phuong, additional, Greipp, Patricia, additional, Foran, James, additional, Begna, Kebede, additional, Gangat, Naseema, additional, Patnaik, Mrinal, additional, Tefferi, Ayalew, additional, Litzow, Mark, additional, Mangaonkar, Abhishek, additional, Shah, Mithun Vinod, additional, Badar, Talha, additional, Alkhateeb, Hassan B., additional, and Al-Kali, Aref, additional

Published
2022
Full Text
View/download PDF

31. Comparison between GATA2 and DDX41-mutated myeloid neoplasms

Author

Nanaa, Ahmad, primary, He, Rong, additional, Viswanatha, David, additional, Nguyen, Phuong, additional, Jevremovic, Dragan, additional, Foran, James M., additional, Yi, Cecelia Arana, additional, Greipp, Patricia T., additional, Gangat, Naseema, additional, Patnaik, Mrinal, additional, Tefferi, Ayalew, additional, Litzow, Mark R., additional, Mangaonkar, Abhishek A., additional, Shah, Mithun Vinod, additional, Badar, Talha, additional, Alkhateeb, Hassan B., additional, and Al-Kali, Aref, additional

Published
2022
Full Text
View/download PDF

32. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents

Author

Johnson, Isla M., primary, Bezerra, Evandro D., additional, Farrukh, Faiqa, additional, McCullough, Kristen, additional, Al-Kali, Aref, additional, Alkhateeb, Hassan B., additional, Begna, Kebede, additional, Litzow, Mark R., additional, Hogan, William J., additional, Shah, Mithun Vinod, additional, Patnaik, Mrinal M., additional, Tefferi, Ayalew, additional, and Gangat, Naseema, additional

Published
2022
Full Text
View/download PDF

33. Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.

Author

Ragon, Brittany K., primary, D'Souza, Anita, additional, Estrada-Merly, Noel, additional, Fraser, Raphael, additional, George, Gemlyn, additional, Gowda, Lohith, additional, Shah, Nina, additional, Qazilbash, Muzaffar H., additional, Kumar, Shaji, additional, Horowitz, Mary M., additional, Usmani, Saad Zafar, additional, and Shah, Mithun Vinod, additional

Published
2022
Full Text
View/download PDF

34. Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.

Author

Mangaonkar, Abhishek Avinash, primary, Arana Yi, Cecilia Ysabel, additional, Murthy, Hemant S., additional, Badar, Talha, additional, Foran, James M., additional, Geyer, Susan Michelle, additional, McCullough, Kristen Beth, additional, Baba Lola, Erinayo S, additional, Hanson, Jean, additional, Al-Kali, Aref, additional, Alkhateeb, Hassan B., additional, Shah, Mithun Vinod, additional, Begna, Kebede, additional, Elliott, Michelle A., additional, Gangat, Naseema, additional, Litzow, Mark Robert, additional, Wolanskyj-Spinner, Alexandra P., additional, Hogan, William J., additional, Tefferi, Ayalew, additional, and Patnaik, Mrinal, additional

Published
2022
Full Text
View/download PDF

35. Characteristics and prognosis of DDX41- and GATA2-mutated myeloid neoplasms.

Author

Nanaa, Ahmad, primary, Alkhateeb, Hassan B., additional, Badar, Talha, additional, Foran, James M., additional, Sproat, Lisa Ostrosky, additional, Arana Yi, Cecilia Ysabel, additional, Nguyen, Phuong L., additional, Jevremovic, Dragan, additional, Greipp, Patricia T., additional, Gangat, Naseema, additional, Tefferi, Ayalew, additional, Litzow, Mark Robert, additional, Shah, Mithun Vinod, additional, Mangaonkar, Abhishek Avinash, additional, Patnaik, Mrinal, additional, Viswanatha, David, additional, He, Rong, additional, and Al-Kali, Aref, additional

Published
2022
Full Text
View/download PDF

36. Characteristics and prognosis of mutated STAG2 myeloid neoplasms.

Author

Katamesh, Bahga, primary, Nanaa, Ahmad, additional, He, Rong, additional, Viswanatha, David, additional, Nguyen, Phuong L., additional, Greipp, Patricia T., additional, Gangat, Naseema, additional, Begna, Kebede, additional, Mangaonkar, Abhishek Avinash, additional, Patnaik, Mrinal, additional, Hogan, William J., additional, Litzow, Mark Robert, additional, Shah, Mithun Vinod, additional, Arana Yi, Cecilia Ysabel, additional, Foran, James M., additional, Badar, Talha, additional, Alkhateeb, Hassan B., additional, and Al-Kali, Aref, additional

Published
2022
Full Text
View/download PDF

37. Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms

Author

Shah, Mithun Vinod, primary, Chhetri, Rakchha, additional, Dholakia, Ruchita, additional, Kok, Chung H., additional, Gangat, Naseema, additional, Alkhateeb, Hassan B., additional, Al‐Kali, Aref, additional, Patnaik, Mrinal M., additional, Baranwal, Anmol, additional, Greipp, Patricia T., additional, He, Rong, additional, Begna, Kebede H., additional, Tiong, Ing Soo, additional, Wei, Andrew H., additional, and Hiwase, Devendra, additional

Published
2022
Full Text
View/download PDF

38. Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning

Author

Kutzke, Jade L, primary, Merten, Julianna A, additional, Pawlenty, Amanda G, additional, Barreto, Erin F, additional, Bartoo, Gabriel T, additional, Mara, Kristin C, additional, Litzow, Mark R, additional, Hogan, William J, additional, Shah, Mithun Vinod, additional, Mangaonkar, Abhishek A, additional, Leung, Nelson, additional, and Alkhateeb, Hassan B, additional

Published
2022
Full Text
View/download PDF

39. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis

Author

Mei, Matthew, primary, Pillai, Raju, additional, Kim, Soyoung, additional, Estrada-Merly, Noel, additional, Afkhami, Michelle, additional, Yang, Lixin, additional, Meng, Zhuo, additional, Abid, Muhammad Bilal, additional, Aljurf, Mahmoud, additional, Bacher, Ulrike, additional, Beitinjaneh, Amer, additional, Bredeson, Christopher, additional, Cahn, Jean-Yves, additional, Cerny, Jan, additional, Copelan, Edward, additional, Cutler, Corey, additional, DeFilipp, Zachariah, additional, Diaz Perez, Miguel Angel, additional, Farhadfar, Nosha, additional, Freytes, César O., additional, Gadalla, Shahinaz M., additional, Ganguly, Siddhartha, additional, Gale, Robert Peter, additional, Gergis, Usama, additional, Grunwald, Michael R., additional, Hamilton, Betty K., additional, Hashmi, Shahrukh, additional, Hildebrandt, Gerhard C., additional, Lazarus, Hillard M., additional, Litzow, Mark, additional, Munker, Reinhold, additional, Murthy, Hemant S., additional, Nathan, Sunita, additional, Nishihori, Taiga, additional, Patel, Sagar S., additional, Rizzieri, David, additional, Seo, Sachiko, additional, Shah, Mithun Vinod, additional, Solh, Melhem, additional, Verdonck, Leo F., additional, Vij, Ravi, additional, Sobecks, Ronald M., additional, Oran, Betul, additional, Scott, Bart L., additional, Saber, Wael, additional, and Nakamura, Ryotaro, additional

Published
2022
Full Text
View/download PDF

41. Genetic features and clinical outcomes of patients with isolated and comutatedDDX41-mutated myeloid neoplasms

Author

Alkhateeb, Hassan B., primary, Nanaa, Ahmad, additional, Viswanatha, David, additional, Foran, James M., additional, Badar, Talha, additional, Sproat, Lisa, additional, He, Rong, additional, Nguyen, Phuong, additional, Jevremovic, Dragan, additional, Salama, Mohamad E., additional, Greipp, Patricia, additional, Gangat, Naseema, additional, Tefferi, Ayalew, additional, Litzow, Mark R., additional, Mangaonkar, Abhishek A., additional, Shah, Mithun Vinod, additional, Patnaik, Mrinal, additional, and Al-Kali, Aref, additional

Published
2022
Full Text
View/download PDF

43. TP53mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Author

Hiwase, Devendra, Hahn, Christopher, Tran, Elizabeth Ngoc Hoa, Chhetri, Rakchha, Baranwal, Anmol, Al-Kali, Aref, Sharplin, Kirsty, Ladon, Dariusz, Hollins, Rachel, Greipp, Patricia, Kutyna, Monika, Alkhateeb, Hassan, Badar, Talha, Wang, Paul, Ross, David M., Singhal, Deepak, Shanmuganathan, Naranie, Bardy, Peter, Beligaswatte, Ashanka, Yeung, David, Litzow, Mark R., Mangaonkar, Abhishek, Giri, Pratyush, Lee, Cindy, Yong, Angie, Horvath, Noemi, Singhal, Nimit, Gowda, Raghu, Hogan, William, Gangat, Naseema, Patnaik, Mrinal, Begna, Kebede, Tiong, Ing S., Wei, Andrew, Kumar, Sharad, Brown, Anna, Scott, Hamish, Thomas, Daniel, Kok, Chung H., Tefferi, Ayalew, and Shah, Mithun Vinod

Abstract

[Display omitted]

Published
2023
Full Text
View/download PDF

44. A population‐based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series.

Author

Smith, Caleb J., Thomas, John W., Ruan, Gordon, Hyun, Meredith C., Bansal, Radhika, McLaughlin, Nicole, Pardanani, Animesh, Gangat, Naseema, Go, Ronald S., Szuber, Natasha, Goyal, Gaurav, Shah, Mithun Vinod, and Tefferi, Ayalew

Published
2021
Full Text
View/download PDF

46. Phase 1 study to determine the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in patients with proliferative chronic myelomonocytic leukemia relapsed/refractory or intolerant to available therapies.

Author

McCullough, Kristen, Mangaonkar, Abhishek A, Burgess, Ashya R., Al-Kali, Aref, Alkhateeb, Hassan B., Begna, Kebede, Gangat, Naseema, Geyer, Susan Michelle, Hogan, William J., Litzow, Mark Robert, Reichard, Kaaren, Saliba, Antoine N, Shah, Mithun Vinod, Wolanskyj-Spinner, Alexandra P., and Patnaik, Mrinal Mahesh

Published
2023
Full Text
View/download PDF

48. Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms

Author

Anmol Baranwal, Christopher N. Hahn, Mithun Vinod Shah, Devendra K. Hiwase, Baranwal, Anmol, Hahn, Christopher N, Shah, Mithun Vinod, and Hiwase, Devendra K

Subjects
genetic predisposition to disease, Cancer Research, poly (ADP-ribose) polymerase inhibitors, therapy-associated neoplasms, Oncology, clonal hematopoiesis, DNA damage, Hematology, germ-line mutation
Abstract

Refereed/Peer-reviewed Purpose of Review: Therapy-related myeloid neoplasms (t-MNs) are aggressive leukemias that develop following exposure to DNA-damaging agents. A subset of patients developing t-MN may have an inherited susceptibility to develop myeloid neoplasia. Herein, we review studies reporting t-MN and their association with a germline or inherited predisposition. Recent Findings: Emerging evidence suggests that development of t-MN is the result of complex interactions including generation of somatic variants in hematopoietic stem cells and/or clonal selection pressure exerted by the DNA-damaging agents, and immune evasion on top of any inherited genetic susceptibility. Conventionally, alkylating agents, topoisomerase inhibitors, and radiation have been associated with t-MN. Recently, newer modalities including poly (ADP-ribose) polymerase inhibitors (PARPi) and peptide receptor radionucleotide therapy (PRRT) are associated with t-MN. At the same time, the role of pathogenic germline variants (PGVs) in genes such as BRCA1/2, BARD1, or TP53 on the risk of t-MN is being explored. Moreover, studies have shown that while cytotoxic therapy increases the risk of developing myeloid neoplasia, it may be exposing the vulnerability of an underlying germline predisposition. Summary: t-MN remains a disease with poor prognosis. Studies are needed to better define an individual’s inherited neoplastic susceptibility which will help predict the risk of myeloid neoplasia in the future. Understanding the genes driving the inherited neoplastic susceptibility will lead to better patient- and cancer-specific management including choice of therapeutic regimen to prevent, or at least delay, development of myeloid neoplasia after treatment of a prior malignancy.

Published
2022

49. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms

Author

Mithun Vinod Shah, Elizabeth Ngoc Hoa Tran, Syed Shah, Rakchha Chhetri, Anmol Baranwal, Dariusz Ladon, Carl Shultz, Aref Al-Kali, Anna L. Brown, Dong Chen, Hamish S. Scott, Patricia Greipp, Daniel Thomas, Hassan B. Alkhateeb, Deepak Singhal, Naseema Gangat, Sharad Kumar, Mrinal M. Patnaik, Christopher N. Hahn, Chung Hoow Kok, Ayalew Tefferi, Devendra K. Hiwase, Shah, Mithun Vinod, Tran, Elizabeth Ngoc Hoa, Shah, Syed, Chhetri, Rakchha, Brown, Anna L, Scott, Hamish S, Kumar, Sharad, Hahn, Christopher N, Kok, Chung Hoow, and Hiwase, Devendra K

Subjects
Oncology, Tumor protein p53 (TP53), myeloid neoplasms (MN), poor prognostic impact, Hematology, World Health Organization
Abstract

Revised diagnostic criteria for myeloid neoplasms (MN) issued by the International Consensus Classification (ICC) and the World Health Organization (WHO) recommended major change pertaining to TP53-mutated (TP53mut) MN. However, these assertions have not been specifically examined in therapy-related myeloid neoplasm (t-MN), a subset enriched with TP53mut. We analyzed 488 t-MN patients for TP53mut. At least one TP53mut with variant allele frequency (VAF) ≥ 2% with or without loss of TP53 locus was noted in 182 (37.3%) patients and 88.2% of TP53mut t-MN had a VAF ≥10%. TP53mut t-MN with VAF ≥ 10% had a distinct clinical and biological profile compared to both TP53mut VAF TP53 (TP53wt) cases. Notably, TP53mut VAF ≥ 10% had a significantly shorter survival compared to TP53wt (8.3 vs. 21.6 months; P TP53mut VAF TP53wt. Within TP53mut VAF ≥ 10% cohort, the inferior outcomes persisted irrespective of the single- or multi-hit status, co-mutation pattern, or treatments received. Finally, survival of TP53mut patients was poor across all the blast categories and MDS patients with >10% blasts had inferior survival compared to TP53mut VAF ≥10% signified a clinically and molecularly homogenous cohort regardless of the allelic status.

Published
2023

50. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Author

Devendra Hiwase, Christopher Hahn, Elizabeth Ngoc Hoa Tran, Rakchha Chhetri, Anmol Baranwal, Aref Al-Kali, Kirsty Sharplin, Dariusz Ladon, Rachel Hollins, Patricia Greipp, Monika Kutyna, Hassan Alkhateeb, Talha Badar, Paul Wang, David M. Ross, Deepak Singhal, Naranie Shanmuganathan, Peter Bardy, Ashanka Beligaswatte, David Yeung, Mark R. Litzow, Abhishek Mangaonkar, Pratyush Giri, Cindy Lee, Angie Yong, Noemi Horvath, Nimit Singhal, Raghu Gowda, William Hogan, Naseema Gangat, Mrinal Patnaik, Kebede Begna, Ing S. Tiong, Andrew Wei, Sharad Kumar, Anna Brown, Hamish Scott, Daniel Thomas, Chung H. Kok, Ayalew Tefferi, Mithun Vinod Shah, Hiwase, Devendra, Hahn, Christopher, Tran, Elizabeth Ngoc Hoa, Chhetri, Rakchha, Wang, Paul, Kumar, Sharad, Brown, Anna, Scott, Hamish, Kok, Chung H, and Shah, Mithun Vinod

Subjects
Immunology, TP53 mutation, Cell Biology, Hematology, acute myeloid leukemia, high-throughput nucleotide sequencing, Biochemistry, Bohring Syndrome
Published
2022

Catalog

Books, media, physical & digital resources
See catalog results